Douglas A Levine MD
Douglas A Levine MD
NYU Langone Health
Verified email at nyumc.org
Title
Cited by
Cited by
Year
Integrated genomic characterization of endometrial carcinoma
DA Levine
Nature 497 (7447), 67-73, 2013
28772013
Inferring tumour purity and stromal and immune cell admixture from expression data
K Yoshihara, M Shahmoradgoli, E Martínez, R Vegesna, H Kim, ...
Nature communications 4 (1), 1-11, 2013
17622013
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
13962018
Absolute quantification of somatic DNA alterations in human cancer
SL Carter, K Cibulskis, E Helman, A McKenna, H Shen, T Zack, PW Laird, ...
Nature biotechnology 30 (5), 413-421, 2012
13642012
Integrated genomic analyses of ovarian carcinoma
D Bell, A Berchuck, M Birrer, J Chien, DW Cramer, F Dao, R Dhir, ...
Nature Publishing Group, 2011
12352011
Rethinking ovarian cancer: recommendations for improving outcomes
S Vaughan, JI Coward, RC Bast, A Berchuck, JS Berek, JD Brenton, ...
Nature Reviews Cancer 11 (10), 719-725, 2011
11862011
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
10592018
Evaluating cell lines as tumour models by comparison of genomic profiles
S Domcke, R Sinha, DA Levine, C Sander, N Schultz
Nature communications 4 (1), 1-10, 2013
10272013
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
9542018
Resistance to therapy caused by intragenic deletion in BRCA2
SL Edwards, R Brough, CJ Lord, R Natrajan, R Vatcheva, DA Levine, ...
Nature 451 (7182), 1111-1115, 2008
8702008
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
8492018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
8442018
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
7812017
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast, V Beral, JS Berek, ...
Nature reviews Cancer 15 (11), 668-679, 2015
6852015
Network modeling links breast cancer susceptibility and centrosome dysfunction
MA Pujana, JDJ Han, LM Starita, KN Stevens, M Tewari, JS Ahn, ...
Nature genetics 39 (11), 1338-1349, 2007
6722007
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
DS Chi, EL Eisenhauer, J Lang, J Huh, L Haddad, NR Abu-Rustum, ...
Gynecologic oncology 103 (2), 559-564, 2006
6182006
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
KL Bolton, G Chenevix-Trench, C Goh, S Sadetzki, SJ Ramus, BY Karlan, ...
Jama 307 (4), 382-389, 2012
5492012
Integrated proteogenomic characterization of human high-grade serous ovarian cancer
H Zhang, T Liu, Z Zhang, SH Payne, B Zhang, JE McDermott, JY Zhou, ...
Cell 166 (3), 755-765, 2016
5462016
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
5432013
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm
DS Chi, EL Eisenhauer, O Zivanovic, Y Sonoda, NR Abu-Rustum, ...
Gynecologic oncology 114 (1), 26-31, 2009
5422009
The system can't perform the operation now. Try again later.
Articles 1–20